BSG response to NICE consultation on biologics
Professor Chris Probert, Chair BSG IBD Section Committee
The BSG has responded to NICE's interim evaluation of whether infliximab, adalimumab and golimumab should be available for patients with moderate to severe ulcerative colitis. The response was drawn up with input from members of the IBD Committee as well as Section members who approached us because of their particular expertise. We are very grateful for their time and effort on behalf of our patients.
Our response as key stakeholders runs in parallel with responses from ACP, RCP, the IBD Nurses and CCUK. The patients themselves have arranged an e-petition with roughly 2000 signatures. I think jointly we have expressed our views very strongly. This issue is unlikely to be resolved in the next few months, in the meantime NICE are considering Vedolizumab, so watch this space.
- View BSG response [ 70 kb ]
New Evidence Update on Crohn's disease from NICE
An Evidence Update on Crohn's disease has been published by NICE.
NICE Evidence Updates help to reduce the need for individuals, managers and commissioners to search for new evidence and keep health and social care professionals up-to-date with new research. While Evidence Updates do not replace current accredited guidance and do not provide formal recommendations, they do highlight new evidence that health and social care professionals may wish to consider alongside current guidance.
The new Evidence Update focuses on a summary of selected new evidence relevant to NICE clinical guideline 152 'Crohn's disease: management in adults, children and young people' (2012).
IBD Registry Preliminary Data Presented
At BSG 2014, Clinical Lead, Dr Fraser Cummings presented the first data on over 4000 patients from the UK IBD Registry. This presentation gives an idea of the trends that can be observed using Registry data, such as patients' smoking status or medication. One important development is the linkage with Hospital Episode Statistics (HES) data, which shows healthcare utilisation, e.g. the number of outpatient appointments and A&E admissions each year.
Early Adopters' Lead, Dr Matthew Johnson provided practical advice on using the Registry Patient Management System (PMS) to support patient care, and explained how he and his team at Luton and Dunstable University Hospital have successfully used the system to fund an additional IBD specialist nurse.
We also launched our new Registry Information Pack, a step-by-step guide to joining the IBD Registry, including information for clinical teams, IT and Caldicott Guardians as well as an example business case, PMS screen shots and letters.
Setting the Registry within the broader context of raising standards in IBD, the panel also included Professor Mark Baker, Director of the NICE Centre for Clinical Practice, Dr Ian Arnott, Clinical Lead of the UK IBD Audit and David Barker, Chief Executive of Crohn's and Colitis UK and Chair of IBD Standards and Dr Stuart Bloom, Chair of IBD Registry.
Summing up the meeting, Crohn's and Colitis UK Chief Executive, David Barker commented: "The work of the IBD Standards, Audit and Registry are really critical in terms of driving up standards of care for patients."
ECCO 2015: Challenging Cases
Present a challenging case at the ECCO Congress 2015 in Barcelona
SciCom opens the call for challenging cases for the ECCO Congress 2015 in Barcelona. Calls submitted should relate to one of the following three clinical dilemmas:
- Risk of cancer in chronic perianal disease
- Risk of infection occurring under biological treatment (anti-TNF, immunosuppressant)
- Loss of response to anti-TNF in paediatrics
Please note that your case does not necessarily need to be a rare case and can represent an everyday struggle.
In the selection process, priority will be given to cases reflecting one of the session titles. Please also consider how the case complements the overall programme.
Questions about applying to the EME researcher-led workstream?
Page 1 of 3